Myeloid-derived suppressor cells mediate tolerance induction in autoimmune disease

Immunology

Volumn 151, Issue 1, 2017, Pages 26-42

  Wegner, Anja ^a,b   Verhagen, Johan ^a,b   Wraith, David C ^a,c  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

autoimmune disease; experimental autoimmune encephalomyelitis; immunotherapy; myeloid derived suppressor cells; tolerance

Indexed keywords

ARGINASE 1; INTERLEUKIN 10; INTERLEUKIN 10 RECEPTOR; MYELIN BASIC PROTEIN; ARG1 PROTEIN, MOUSE; ARGINASE; MYELIN BASIC PROTEIN 1-11; PEPTIDE FRAGMENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; CELL CONTACT; CONTROLLED STUDY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; IMMUNOLOGICAL TOLERANCE; IMMUNOPHENOTYPING; IMMUNOTHERAPY; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MOUSE; MULTIPLE SCLEROSIS; MYELOID-DERIVED SUPPRESSOR CELL; NONHUMAN; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; PROTECTION; SIGNAL TRANSDUCTION; SPLENECTOMY; TH1 CELL; ANIMAL; CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PROCEDURES; TRANSGENIC MOUSE; TRANSPLANTATION;

ANIMALS; ARGINASE; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; IMMUNE TOLERANCE; IMMUNOPHENOTYPING; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MICE; MICE, TRANSGENIC; MULTIPLE SCLEROSIS; MYELIN BASIC PROTEIN; MYELOID-DERIVED SUPPRESSOR CELLS; PEPTIDE FRAGMENTS;

EID: 85014086326     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12718     Document Type: Article

References (37)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000; 343:938–52.
2. Fairchild PJ, Wildgoose R, Atherton E, Webb S, Wraith DC. An autoantigenic T cell epitope forms unstable complexes with class II MHC: a novel route for escape from tolerance induction. Int Immunol 1993; 5:1151–8.
3. Gabrysova L, Nicolson KS, Streeter HB, Verhagen J, Sabatos-Peyton CA, Morgan DJ et al. Negative feedback control of the autoimmune response through antigen-induced differentiation of IL-10-secreting Th1 cells. J Exp Med 2009; 206:1755–67.
4. Sabatos-Peyton CA, Verhagen J, Wraith DC. Antigen-specific immunotherapy of autoimmune and allergic diseases. Curr Opin Immunol 2010; 22:609–15.
5. Burton BR, Britton GJ, Fang H, Verhagen J, Smithers B, Sabatos-Peyton CA et al. Sequential transcriptional changes dictate safe and effective antigen-specific immunotherapy. Nat Commun 2014; 5:4741.
6. + myeloid cells. J Immunol 2010; 185:1383–92.
7. Buessow SC, Paul RD, Lopez DM. Influence of mammary tumor progression on phenotype and function of spleen and in situ lymphocytes in mice. J Natl Cancer Inst 1984; 73:249–55.
8. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 2001; 166:678–89.
9. Kusmartsev S, Gabrilovich DI. Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol Immunother 2006; 55:237–45.
10. Yin B, Ma G, Yen CY, Zhou Z, Wang GX, Divino CM et al. Myeloid-derived suppressor cells prevent type 1 diabetes in murine models. J Immunol 2010; 185:5828–34.
11. hi suppressive monocytes in experimental autoimmune encephalomyelitis. J Immunol 2007; 179:5228–37.
12. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 2008; 181:5791–802.
13. Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun 2016; 7:12150.
14. Bronte V, Zanovello P. Regulation of immune responses by l-arginine metabolism. Nat Rev Immunol 2005; 5:641–54.
15. Rodriguez PC, Ochoa AC. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev 2008; 222:180–91.
16. Yu J, Du W, Yan F, Wang Y, Li H, Cao S et al. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol 2013; 190:3783–97.
17. + immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 2006; 66:1123–31.
18. Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 2014; 124:687–95.
19. Pan PY, Ma G, Weber KJ, Ozao-Choy J, Wang G, Yin B et al. Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res 2010; 70:99–108.
20. + myeloid cells. Cancer Res 2006; 66:6807–15.
21. Liu GY, Fairchild PJ, Smith RM, Prowle JR, Kioussis D, Wraith DC. Low avidity recognition of self-antigen by T cells permits escape from central tolerance. Immunity 1995; 3:407–15.
22. hi monocytes are crucial for the effector phase of autoimmunity in the central nervous system. Brain 2009; 132:2487–500.
23. + myeloid cells can promote Th17 cell differentiation and experimental autoimmune encephalomyelitis. J Immunol 2012; 189:4295–304.
24. Ioannou M, Alissafi T, Lazaridis I, Deraos G, Matsoukas J, Gravanis A et al. Crucial role of granulocytic myeloid-derived suppressor cells in the regulation of central nervous system autoimmune disease. J Immunol 2012; 188:1136–46.
25. Liu G, Bi Y, Shen B, Yang H, Zhang Y, Wang X et al. SIRT1 limits the function and fate of myeloid-derived suppressor cells in tumors by orchestrating HIF-1α-dependent glycolysis. Cancer Res 2014; 74:727–37.
26. Dolcetti L, Peranzoni E, Ugel S, Marigo I, Fernandez Gomez A, Mesa C et al. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol 2010; 40:22–35.
27. Ribechini E, Greifenberg V, Sandwick S, Lutz MB. Subsets, expansion and activation of myeloid-derived suppressor cells. Med Microbiol Immunol 2010; 199:273–81.
28. Novitskiy SV, Pickup MW, Gorska AE, Owens P, Chytil A, Aakre M et al. TGF-β receptor II loss promotes mammary carcinoma progression by Th17 dependent mechanisms. Cancer Discov 2011; 1:430–41.
29. Parker KH, Beury DW, Ostrand-Rosenberg S. Myeloid-derived suppressor cells: critical cells driving immune suppression in the tumor microenvironment. Adv Cancer Res 2015; 128:95–139.
30. Yang Z, Zhang B, Li D, Lv M, Huang C, Shen GX et al. Mast cells mobilize myeloid-derived suppressor cells and Treg cells in tumor microenvironment via IL-17 pathway in murine hepatocarcinoma model. PLoS ONE 2010; 5:e8922.
31. Corzo CA, Condamine T, Lu L, Cotter MJ, Youn JI, Cheng P et al. HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med 2010; 207:2439–53.
32. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162–74.
33. Hart KM, Byrne KT, Molloy MJ, Usherwood EM, Berwin B. IL-10 immunomodulation of myeloid cells regulates a murine model of ovarian cancer. Front Immunol 2011; 2:29.
34. Dugast AS, Haudebourg T, Coulon F, Heslan M, Haspot F, Poirier N et al. Myeloid-derived suppressor cells accumulate in kidney allograft tolerance and specifically suppress effector T cell expansion. J Immunol 2008; 180:7898–906.
35. Suh ED, Vistica BP, Chan CC, Raber JM, Gery I, Nussenblatt RB. Splenectomy abrogates the induction of oral tolerance in experimental autoimmune uveoretinitis. Curr Eye Res 1993; 12:833–9.
36. Buettner M, Bornemann M, Bode U. Skin tolerance is supported by the spleen. Scand J Immunol 2013; 77:238–45.
37. Flugel A, Berkowicz T, Ritter T, Labeur M, Jenne DE, Li Z et al. Migratory activity and functional changes of green fluorescent effector cells before and during experimental autoimmune encephalomyelitis. Immunity 2001; 14:547–60.